DE69716469T2 - Pharmazeutische zusammensetzung enthaltend ein osteogenese foerderndes mittel und ein polyethylen-glycol - Google Patents

Pharmazeutische zusammensetzung enthaltend ein osteogenese foerderndes mittel und ein polyethylen-glycol

Info

Publication number
DE69716469T2
DE69716469T2 DE69716469T DE69716469T DE69716469T2 DE 69716469 T2 DE69716469 T2 DE 69716469T2 DE 69716469 T DE69716469 T DE 69716469T DE 69716469 T DE69716469 T DE 69716469T DE 69716469 T2 DE69716469 T2 DE 69716469T2
Authority
DE
Germany
Prior art keywords
pharmaceutical composition
polyethylene glycol
osteogenese
composition containing
promoting agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69716469T
Other languages
English (en)
Other versions
DE69716469D1 (de
Inventor
Tetsuo Hoshino
Kazuhiro Saito
Susumu Iwasa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of DE69716469D1 publication Critical patent/DE69716469D1/de
Publication of DE69716469T2 publication Critical patent/DE69716469T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
DE69716469T 1996-08-26 1997-08-25 Pharmazeutische zusammensetzung enthaltend ein osteogenese foerderndes mittel und ein polyethylen-glycol Expired - Lifetime DE69716469T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP22344396 1996-08-26
JP9040897 1997-04-09
PCT/JP1997/002941 WO1998008517A2 (en) 1996-08-26 1997-08-25 Pharmaceutical composition containing osteogenesis-promoting substance and a polyethylene glycol

Publications (2)

Publication Number Publication Date
DE69716469D1 DE69716469D1 (de) 2002-11-21
DE69716469T2 true DE69716469T2 (de) 2003-02-20

Family

ID=26431895

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69716469T Expired - Lifetime DE69716469T2 (de) 1996-08-26 1997-08-25 Pharmazeutische zusammensetzung enthaltend ein osteogenese foerderndes mittel und ein polyethylen-glycol

Country Status (9)

Country Link
US (1) US6190695B1 (de)
EP (1) EP0949927B1 (de)
AT (1) ATE226078T1 (de)
AU (1) AU3868997A (de)
CA (1) CA2264131A1 (de)
DE (1) DE69716469T2 (de)
ES (1) ES2181017T3 (de)
ID (1) ID18079A (de)
WO (1) WO1998008517A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
CA2334815A1 (en) * 1998-06-15 1999-12-23 Haruhiko Makino Composition for treating cartilage disease
US6355672B1 (en) 1998-08-07 2002-03-12 Takeda Chemical Industries, Ltd. Benzothiepin derivatives, process for the preparation of the same and uses thereof
CA2340165A1 (en) * 1998-08-12 2000-02-24 Haruhiko Makino Enhancer of cell differentiation induction factor
AU6318900A (en) * 1999-08-05 2001-03-05 Takeda Chemical Industries Ltd. Pastes with the sustained release of osteogenesis promoter
WO2001097784A1 (fr) * 2000-06-23 2001-12-27 Takeda Chemical Industries, Ltd. Procede de production de medicaments contenant des phospholipides
EP1352661B1 (de) * 2001-01-19 2014-08-27 Hironori Yamamoto Injektionen für die endoskopie
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
US8158685B2 (en) * 2004-07-02 2012-04-17 Gregory Gene Steiner Method for bone growth
HUE029572T2 (en) 2006-02-03 2017-03-28 Opko Renal Llc Treatment of Vitamin D Insufficiency and Deficiency with 25-Hydroxy-D2 and 25-Hydroxy-D3
US8329677B2 (en) 2006-06-21 2012-12-11 Cytochroma, Inc. Method of treating and preventing secondary hyperparathyroidism
WO2008134518A2 (en) * 2007-04-25 2008-11-06 Cytochroma Inc. Methods and compounds for vitamin d therapy
WO2008134523A1 (en) * 2007-04-25 2008-11-06 Proventiv Therapeutics, Llc Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
KR101495578B1 (ko) * 2007-04-25 2015-02-25 사이토크로마 인코포레이티드 비타민 d 부족 및 결핍의 치료 방법
EP3542792B1 (de) 2007-04-25 2023-06-28 EirGen Pharma Ltd. Kontrollierte freisetzung 25-hydroxyvitamin d
KR101852042B1 (ko) 2008-04-02 2018-04-25 사이토크로마 인코포레이티드 비타민 d 결핍 및 관련 장애에 유용한 방법, 조성물, 용도 및 키트
LT2552484T (lt) 2010-03-29 2020-04-27 Opko Ireland Global Holdings, Ltd. Būdai ir kompozicijos, skirti paratiroidų lygiams sumažinti
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 d 방출 제형
CN114681468A (zh) 2014-08-07 2022-07-01 欧普科爱尔兰环球控股有限公司 利用25-羟基维生素d的辅助疗法
TW202214257A (zh) 2016-03-28 2022-04-16 愛爾蘭商歐科愛爾蘭全球控股股份有限公司 維生素d治療之方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4906475A (en) * 1988-02-16 1990-03-06 Paco Pharmaceutical Services Estradiol transdermal delivery system
NZ231939A (en) 1988-12-28 1991-07-26 Takeda Chemical Industries Ltd Benzothiopyran derivatives and medicaments
EP0460488B1 (de) * 1990-05-30 2001-07-11 Takeda Chemical Industries, Ltd. Schwefel enthaltende heterocyclische Verbindungen
WO1994023740A1 (en) * 1993-04-22 1994-10-27 Celtrix Pharmaceuticals, Inc. Conjugates of growth factor and bone resorption inhibitor
JP3319625B2 (ja) * 1993-05-12 2002-09-03 ホーユー株式会社 速崩壊性生薬製剤
TW403757B (en) * 1994-12-28 2000-09-01 Takeda Chemical Industries Ltd Optically active benzothiepin derivative, its preparation and use
RU2188011C2 (ru) * 1995-06-05 2002-08-27 Такеда Кемикал Индастриз, Лтд. Активирующая остеогенез фармацевтическая композиция

Also Published As

Publication number Publication date
US6190695B1 (en) 2001-02-20
WO1998008517A2 (en) 1998-03-05
CA2264131A1 (en) 1998-03-05
EP0949927A2 (de) 1999-10-20
ES2181017T3 (es) 2003-02-16
EP0949927B1 (de) 2002-10-16
AU3868997A (en) 1998-03-19
ATE226078T1 (de) 2002-11-15
WO1998008517A3 (en) 1998-05-07
ID18079A (id) 1998-02-26
DE69716469D1 (de) 2002-11-21

Similar Documents

Publication Publication Date Title
DE69716469T2 (de) Pharmazeutische zusammensetzung enthaltend ein osteogenese foerderndes mittel und ein polyethylen-glycol
DE69823869D1 (de) Pharmazeutische hydrogelformulierungen, vorrichtungen zur arzneistoffabgabe und verfahren
DE69808297T2 (de) Oral anzuwendende arzneizubereitungen enthaltend eine benzhydrylpiperazine und eine zyklodextrin
ATE447947T1 (de) Pharmazeutische zubereitungen zur behandlung von insulinresitenz
DE69801045D1 (de) Pharmazeutische zusammensetzung zur oralen verabreichung von einem n-piperidin-3-pyrazolcarboxamid-derivat, dessen salzen und deren solvaten
DE50005529D1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
DE69501419T2 (de) Pharmazeutische Zusammensetzung zur Behandlung von Osteoporose enthaltend Xanthohumol
ATE395071T1 (de) Pharmazeutische zubereitungen zur angiogenese- therapie
BRPI0008228B8 (pt) composição farmacêutica contendo n-benzoil estaurosporina e agentes solubilizantes
IT1216686B (it) Formulazioni farmaceutiche acquose di piroxicam e procedimento per laloro preparazione.
ATE383868T1 (de) Pharmazeutische formulierung enthaltend megalatran und dessen pro-pharmaka
NO20006646D0 (no) Aminosyrederivater og legemidler inneholdende de samme som aktiv bestanddel
DE69907926D1 (de) 1,2,4-triazol-3-thion verbindungen
ATE247981T1 (de) Proteinenthaltende pharmazeutische zubereitung
ATE464878T1 (de) Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
ATE264309T1 (de) Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren
ATE247466T1 (de) Pharmazeutische zubereitungen enthaltend ibuprofen und domperidon zur behandlung von migräne
WO1999050239A3 (fr) Nouveaux composes heteroethynylenes et compositions pharmaceutiques et cosmetiques les contenant
HRP20000781B1 (en) Effervescent preparations
ATE236885T1 (de) Hydrazono-benzazulen-derivate, pharmazeutische zusammensetzungen und zwischenprodukte
HK1065305A1 (en) Substituted 4-aminocyclohexanol derivatives
ATE402719T1 (de) Injiziebare pharmazeutische zusammensetzung enthaltend ethanol zur behandlung von bandscheibenvorfällen
ES2053679T3 (es) Embonato de azelastina, procedimiento para su preparacion y preparados farmaceuticos que contienen embonato de azelastina como principio activo.
TR199901385T2 (xx) Piperidin t�revleri.

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: TAKEDA PHARMACEUTICAL CO. LTD., OSAKA, JP

8364 No opposition during term of opposition